Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic acid in pediatric heterozygous familial hypercholesterolemia
2018-004084-31Phase 2Active
- Sponsor
- Esperion Therapeutics
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bempedoic acid in heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia, sponsored by Esperion Therapeutics. Primary endpoint: Observed trough plasma concentration of ETC-1002 following 8 weeks of steady-state dosing of bempedoic acid. Started Sep 2022; status: active.
02
Drugs
bempedoic acid
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)hypercholesterolemia
Beyond the preview
Go deeper on 2018-004084-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004084-31.